{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:13:22Z","timestamp":1794276802963,"version":"4.9.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Prescribing information &amp; ADR reporting<\/jats:title>\n                    <jats:p>This is an Astellas article. Prescribing information can be accessed at https:\/\/dhgd52pup2eiv.cloudfront.net\/23ffe42b-4e89-48e1-b8d8-08b726ed94c1\/b5d6cdf5-d05a-4bb1-9965-de9a244d39eb\/b5d6cdf5-d05a-4bb1-9965-de9a244d39eb_source__v.pdf and the adverse event reporting information can be found on the last page of that link.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced urothelial carcinoma (UC) significantly impacts quality of life, is associated with poor prognosis, and carries a high economic burden. Recently, the combination of enfortumab vedotin and pembrolizumab (EV-P) has demonstrated improved progression-free survival vs platinum-based chemotherapy and overall survival, and is now recommended as a first-line therapy for patients with unresectable or metastatic disease who are platinum eligible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multidisciplinary expert panel was convened to review the current UK patient pathway for advanced UC. The panel developed consensus recommendations for implementing EV-P in the United Kingdom and provided guidance on managing adverse events (AEs), taking into account the challenges in the current pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The expert panel recommended leveraging lessons from the previous implementation of new immunotherapies and antibody-drug conjugates as EV-P is implemented across the United Kingdom. They emphasized the importance of peer support from clinical centers involved in the EV-302 phase 3 clinical trial, advocating for the sharing of protocols, advice, and support for toxicity management. Recommendations included establishing robust referral pathways and multidisciplinary care models tailored to the resources and structures of different hospital settings. Education in proactive side effect identification and management was recommended for bladder cancer clinical nurse specialists, acute oncology nurses, pharmacists, and clinicians. The panel developed patient checklists to support clinicians in assessing treatment suitability, monitoring AEs during therapy, and ensuring continued monitoring after treatment ends. Detailed recommendations were provided for managing AEs, with a focus on skin reactions, peripheral neuropathy, hyperglycemia, pneumonitis\/interstitial lung disease, and ocular disorders, along with guidance on when to involve specialist services.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These consensus recommendations provide practical, multidisciplinary guidance to support the effective implementation of EV-P for advanced UC in UK healthcare settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf220","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:40:13Z","timestamp":1756467613000},"source":"Crossref","is-referenced-by-count":5,"title":["Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin\u25bc and pembrolizumab in advanced urothelial carcinoma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1552-511X","authenticated-orcid":false,"given":"Syed","family":"Hussain","sequence":"first","affiliation":[{"name":"School of Medicine and Population Health, Department of Oncology, University of Sheffield , Sheffield S10 2SJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Carr","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University Hospital Southampton NHS Foundation Trust , Southampton SO17 1BJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon John","family":"Crabb","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery (NHNN), University College London Hospitals NHS Trust , London W1T 4JD,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Dodhia","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , East and North Hertfordshire NHS Trust , Northwood WD3 1PZ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Fearfield","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chelsea and Westminster NHS Hospital Trust , London SW10 9NH,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahangeer Mahmood","family":"Malik","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Centre, NHS Lothian , Edinburgh EH4 2XU,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lapuente","sequence":"additional","affiliation":[{"name":"Barts Cancer Research Centre, St Bartholomew\u2019s Hospital , London EC1A 7BS,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davina","family":"Lau","sequence":"additional","affiliation":[{"name":"Astellas Pharma Ltd , Addlestone KT15 2NX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Petruskin","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital , London EC1V 2PD,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sarwar","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London SW7 2BX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Jane","family":"Smith","sequence":"additional","affiliation":[{"name":"HCA Healthcare UK , London NW1 2BU,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stevenson","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust (UHB NHS FT) , Birmingham B15 2GW,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Glasgow , Glasgow G12 0YN,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"2026021723464015700_oyaf220-B1"},{"key":"2026021723464015700_oyaf220-B2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"2026021723464015700_oyaf220-B3"},{"key":"2026021723464015700_oyaf220-B4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41416-023-02543-0","article-title":"Systemic anticancer therapy for urothelial carcinoma: UK oncologists\u2019 perspective","volume":"130","author":"Jones","year":"2024","journal-title":"Br J Cancer"},{"key":"2026021723464015700_oyaf220-B5"},{"key":"2026021723464015700_oyaf220-B6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"2026021723464015700_oyaf220-B7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2026021723464015700_oyaf220-B8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2013.08.049","article-title":"Bladder cancer in Spain 2011: population based study","volume":"191","author":"Mi\u00f1ana","year":"2014","journal-title":"J Urol"},{"key":"2026021723464015700_oyaf220-B9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1200\/JCO.2019.37.7_suppl.380","article-title":"Patient-reported symptoms and impacts of locally advanced or metastatic urothelial cancer (la\/mUC) after chemotherapy followed by a PD-1\/PD-L1 checkpoint inhibitor (CPI)","volume":"37","author":"Shah","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026021723464015700_oyaf220-B10","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s11136-014-0685-9","article-title":"Conceptualizing global health-related quality of life in bladder cancer","volume":"23","author":"Perlis","year":"2014","journal-title":"Qual Life Res"},{"key":"2026021723464015700_oyaf220-B11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/BLC-211518","article-title":"Qualitative analysis of pain in patients with locally advanced or metastatic urothelial carcinoma","volume":"8","author":"Martin","year":"2022","journal-title":"Bladder Cancer"},{"key":"2026021723464015700_oyaf220-B12","doi-asserted-by":"crossref","first-page":"733.e1","DOI":"10.1016\/j.urolonc.2021.05.001","article-title":"Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1\/L1 inhibitor therapy: a Medicare claims database analysis","volume":"39","author":"Morgans","year":"2021","journal-title":"Urol Oncol"},{"key":"2026021723464015700_oyaf220-B13","author":"NHS England"},{"key":"2026021723464015700_oyaf220-B14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"2026021723464015700_oyaf220-B15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 Updated European Association of Urology Guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"2026021723464015700_oyaf220-B16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"2026021723464015700_oyaf220-B17","author":"Cancer Intelligence Team","year":"2025"},{"key":"2026021723464015700_oyaf220-B18","doi-asserted-by":"crossref","first-page":"S1338","DOI":"10.1016\/j.annonc.2022.07.1828","article-title":"1750P factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England","volume":"33","author":"Knott","year":"2022","journal-title":"Ann Oncol."},{"key":"2026021723464015700_oyaf220-B19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-170149","article-title":"Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States","volume":"4","author":"Galsky","year":"2018","journal-title":"Bladder Cancer"},{"key":"2026021723464015700_oyaf220-B20","first-page":"100266","article-title":"Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study","volume":"25","author":"Richters","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"2026021723464015700_oyaf220-B21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/13696998.2019.1591424","article-title":"Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma","volume":"22","author":"Aly","year":"2019","journal-title":"J Med Econ"},{"key":"2026021723464015700_oyaf220-B22","first-page":"100325","article-title":"Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience","volume":"27","author":"Swami","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"2026021723464015700_oyaf220-B23","first-page":"17"},{"key":"2026021723464015700_oyaf220-B24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021723464015700_oyaf220-B25","first-page":"664","volume-title":"J Clin Oncol.","author":"Powles","year":"2025"},{"key":"2026021723464015700_oyaf220-B26","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021723464015700_oyaf220-B27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026021723464015700_oyaf220-B28","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/S1470-2045(24)00345-0","article-title":"NHS cancer services and systems-ten pressure points a UK cancer control plan needs to address","volume":"25","author":"Aggarwal","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026021723464015700_oyaf220-B29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1470-2045(22)00758-6","article-title":"On a precipice: the UK\u2019s broken health-care system","volume":"24","author":"Collingridge","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026021723464015700_oyaf220-B30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1470-2045(22)00754-9","article-title":"UK cancer care: a watershed moment and the need for urgent intervention","volume":"24","author":"Price","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026021723464015700_oyaf220-B31","first-page":"CD013774","article-title":"Immunotherapy for advanced or metastatic urothelial carcinoma","volume":"10","author":"Maisch","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026021723464015700_oyaf220-B32","year":"2025"},{"key":"2026021723464015700_oyaf220-B33","year":"2025"},{"key":"2026021723464015700_oyaf220-B34","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jaad.2019.09.026","article-title":"Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study","volume":"82","author":"Chen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026021723464015700_oyaf220-B35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaad.2022.09.012","article-title":"Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition","volume":"88","author":"Jacoby","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026021723464015700_oyaf220-B36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/jdv.16159","article-title":"Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study","volume":"34","author":"Barrios","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026021723464015700_oyaf220-B37","author":"UK Acute Oncology Society","year":"2024"},{"key":"2026021723464015700_oyaf220-B38","author":"The Immuno-Oncology Clinical Network"},{"key":"2026021723464015700_oyaf220-B39","year":"2025"},{"key":"2026021723464015700_oyaf220-B40","year":"2024"},{"key":"2026021723464015700_oyaf220-B41","year":"2024"},{"key":"2026021723464015700_oyaf220-B42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026021723464015700_oyaf220-B43","doi-asserted-by":"crossref","first-page":"1326715","DOI":"10.3389\/fonc.2024.1326715","article-title":"Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer","volume":"14","author":"Brower","year":"2024","journal-title":"Front Oncol"},{"key":"2026021723464015700_oyaf220-B44","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2024.42.16_suppl.4503","article-title":"Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026021723464015700_oyaf220-B45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021723464015700_oyaf220-B46","volume-title":"KEYTRUDA [Prescribing Information]","year":"2024"},{"key":"2026021723464015700_oyaf220-B47","volume-title":"PADCEV [Prescribing Information]","year":"2024"},{"key":"2026021723464015700_oyaf220-B48","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamadermatol.2021.3450","article-title":"Postmarketing cases of enfortumab vedotin\u2013associated skin reactions reported as Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026021723464015700_oyaf220-B49","doi-asserted-by":"crossref","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026021723464015700_oyaf220-B50","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/bjd\/ljad257","article-title":"How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach","volume":"189","author":"Kawsar","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026021723464015700_oyaf220-B51","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026021723464015700_oyaf220-B52","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026021723464015700_oyaf220-B53","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021723464015700_oyaf220-B54","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"2026021723464015700_oyaf220-B55","author":"British Association of Dermatologists"},{"key":"2026021723464015700_oyaf220-B56","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1188\/21.CJON.E1-E9","article-title":"Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma","volume":"25","author":"Pace","year":"2021","journal-title":"Clin J Oncol Nurs"},{"key":"2026021723464015700_oyaf220-B57","doi-asserted-by":"crossref","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","article-title":"Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"2026021723464015700_oyaf220-B58","doi-asserted-by":"crossref","first-page":"107778","DOI":"10.1016\/j.isci.2023.107778","article-title":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates","volume":"26","author":"Fu","year":"2023","journal-title":"iScience"},{"key":"2026021723464015700_oyaf220-B59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/pn-2024-004327","article-title":"Neurological complications of immune checkpoint inhibitors: a practical guide","volume":"25","author":"Carr","year":"2025","journal-title":"Pract Neurol"},{"key":"2026021723464015700_oyaf220-B60","first-page":"A74.2-A74","article-title":"Immune checkpoint inhibitor neurotoxicity clinic: a service evaluation","volume":"95","author":"Sanketh","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026021723464015700_oyaf220-B61","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021723464015700_oyaf220-B62","doi-asserted-by":"crossref","first-page":"S1441","DOI":"10.1016\/j.annonc.2022.08.079","article-title":"Study EV-103 cohort K: antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"33","author":"Rosenberg","year":"2022","journal-title":"Ann Oncol"},{"key":"2026021723464015700_oyaf220-B63"},{"key":"2026021723464015700_oyaf220-B64","doi-asserted-by":"crossref","first-page":"103725","DOI":"10.1016\/j.esmoop.2024.103725","article-title":"The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria","volume":"9","author":"Apolo","year":"2024","journal-title":"ESMO Open"},{"key":"2026021723464015700_oyaf220-B65","first-page":"A35.2-A35","article-title":"Management of triple M syndrome: a review of immune-checkpoint-inhibitor induced myasthenia gravis, myositis and myocarditis","volume":"95","author":"Isabella","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026021723464015700_oyaf220-B66"},{"key":"2026021723464015700_oyaf220-B67","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1470-2045(23)00216-4","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"24","author":"Giraud","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026021723464015700_oyaf220-B68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-024-01369-0","article-title":"Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors","volume":"63","author":"Tang","year":"2024","journal-title":"Clin Pharmacokinet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf220\/65049410\/oyaf220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf220\/65049410\/oyaf220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T04:46:55Z","timestamp":1771390015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf220\/8306579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf220","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]},"article-number":"oyaf220"}}